This implies that the observed biodistribution of C8–6–I dimer inside the CNS makes it an ideal therapeutic for PD, as this bifunctional drug promotes neuroprotection by inhibiting α-Syn misfolding and aggregation and by suppressing chronic adenosine A1 receptor stimulation, which is expected to prevent α-Syn over-expression. This evidence concerns the gene ADORA1 and Parkinson disease.